Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ULTRA FLUIDE VISAGE - Health Canada Drug Approval Details

Approvals/Health Canada/ULTRA FLUIDE VISAGE

Authorized

STANDARD

ULTRA FLUIDE VISAGE

laboratoires la roche-posay canada🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 7067ce55594e6d72
Company: laboratoires la roche-posay canada
Type: Standard

Approval Details

Approval Id: 7067ce55594e6d72
Drug Approval Canada Name: ULTRA FLUIDE VISAGE
Product Name: ULTRA FLUIDE VISAGE
Status: Marketed
Status Date: 2020-04-15
Original Market Date: 2020-04-15
Din: 02490021
Drug Class: Human
Dosage Form: Lotion
Route Of Administration: Topical
Schedule: OTC
Ahfs: 84:80.00
Atc Original: D02BA30 COMBINATIONS OF PROTECTIVES AGAINST UV-RADIATION
Atc Name: d 02 ba 30
Aig Number: 0761590001
Company Name: laboratoires la roche-posay canada
Company Address: 4895 Hickmore, Montreal, Quebec, Canada, H4T 1K5

Active Ingredients

AVOBENZONE

3 % / W/W

BEMOTRIZINOL

5 % / W/W

ENSULIZOLE

0.5 % / W/W

OCTOCRYLENE

5 % / W/W

DROMETRIZOLE TRISILOXANE

7 % / W/W

HOMOSALATE

2 % / W/W

OCTISALATE

5 % / W/W

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

7067ce55594e6d72

Type

Standard

Back to Health Canada Approvals